MET-233I
A Study of MET233 in Individuals With Obesity or Overweight
Pfizer · Phase 1 · Completed · Enrollment 144
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| (Part A) MET233 | n/r | n/r | n/r | n/r |
| (Part A) Placebo | n/r | n/r | n/r | n/r |
| (Part B) MET233 | n/r | n/r | n/r | n/r |
| (Part B) Placebo | n/r | n/r | n/r | n/r |
| (Part C) MET233 | n/r | n/r | n/r | n/r |
| (Part C) Placebo | n/r | n/r | n/r | n/r |
| (Part D) MET233 | n/r | n/r | n/r | n/r |
| (Part D) Placebo | n/r | n/r | n/r | n/r |
Not shown
- (Part A) MET233: endpoint not reported
- (Part A) Placebo: endpoint not reported
- (Part B) MET233: endpoint not reported
- (Part B) Placebo: endpoint not reported
- (Part C) MET233: endpoint not reported
- (Part C) Placebo: endpoint not reported
- (Part D) MET233: endpoint not reported
- (Part D) Placebo: endpoint not reported